scholarly journals The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019

2020 ◽  
Vol 8 (2) ◽  
pp. e000921
Author(s):  
Paolo A Ascierto ◽  
Carlo Bifulco ◽  
Jerome Galon ◽  
Claus Garbe ◽  
Samir N Khleif ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Cell Therapy ◽  
T Lymphocyte ◽  
Chimeric Antigen Receptor ◽  
Cellular Cytotoxicity ◽  
Antibody Dependent Cellular Cytotoxicity ◽  
T Cell Therapy ◽  
Great Debate ◽  
The Brain

As part of the 2019 Immunotherapy Bridge congress (December 4–5, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on six topical issues in immunotherapy today. These were the use of chimeric antigen receptor T cell therapy in solid tumors, whether the Immunoscore should be more widely used in clinical practice, whether antibody-dependent cellular cytotoxicity is important in the mode of action of anticytotoxic T-lymphocyte-associated protein 4 antibodies, whether the brain is immunologically unique or just another organ, the role of microbiome versus nutrition in affecting responses to immunotherapy, and whether chemotherapy is immunostimulatory or immunosuppressive. Discussion of these important topics are summarized in this report.

scholarly journals Role of bridging therapy during chimeric antigen receptor T cell therapy

eJHaem ◽  
2021 ◽  
Author(s):  
Shakthi T. Bhaskar ◽  
Bhagirathbhai R. Dholaria ◽  
Salyka M. Sengsayadeth ◽  
Bipin N. Savani ◽  
Olalekan O. Oluwole
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Bridging Therapy ◽  
T Cell Therapy

The Role of Granulocyte Transfusions in Optimizing Candidacy for Chimeric Antigen Receptor T-Cell Therapy in Patients With Treatment-refractory Infections

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Francesco P. Tambaro ◽  
Dristhi Ragoonanan ◽  
Priti Tewari ◽  
Demetrios Petropoulos ◽  
Fleur M. Aung ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Treatment Refractory

Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies

Immunotherapy ◽  
2020 ◽  
Vol 12 (18) ◽  
pp. 1341-1357
Author(s):  
Nashwa El-Khazragy ◽  
Sherief Ghozy ◽  
Passant Emad ◽  
Mariam Mourad ◽  
Diaaeldeen Razza ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Hematological Malignancies ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Challenges And Opportunities

Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory hematological malignancies. Despite the great results of the CAR-T-cell therapy, many tumors are still able to avoid immune detection and further elimination, as well as the possible associated adverse events. Herein, we highlighted the recent advances in CAR-T-cell therapy, discussing their applications beneficial functions and side effects in hematological malignancies, illustrating the underlying challenges and opportunities. Furthermore, we provide an overview to overcome different obstacles using potential manufacture and treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document